A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations (clinicaltrials.gov) - Mar 6, 2026 - P2 | N=20 | Completed | Sponsor: Endeavor Biomedicines, Inc. | Active, not recruiting ➔ Completed | N=44 ➔ 20
Enrollment change • Trial completion • Oncology • Solid Tumor • PTCH1
|